Roche convinced new meds can offset biosimilar threats; EU finds no safety issues with Merck, GSK HPV jabs;

@FiercePharma: Australia looks to save cash by cutting scripts for common drugs. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: makes sure Denmark gets some of the action as it starts massive build up. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Allergan pumps up its sales rep tally amid Viberzi launch, aesthetics push. FiercePharmaMarketing story | Follow @CarlyHFierce

> Roche ($RHHBY) is "absolutely convinced" that its new meds will offset biosimilar threats to its older drugs. More

> EU regulators have found no safety concerns linking GlaxoSmithKline's ($GSK) and Merck's ($MRK) HPV shots with two conditions known as complex regional pain syndrome and postural orthostatic tachycardia syndrome. More

> Endo ($ENDP) CEO Rajiv De Silva is working to distance himself and his company from his embattled former employer, Valeant ($VRX). More

Medical Device News

@FierceMedDev: Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss. More | Follow @FierceMedDev

@VarunSaxena2: IYCMI from FierceDrugDelivery: Investigational drug enables faster absorption of bioresorbable drug-eluting stents. Article | Follow @VarunSaxena2

@EmilyWFierce: Medicaid calls on Gilead, AbbVie to answer hep C drug pricing questions. FiercePharma article | Follow @EmilyWFierce

> GAO study finds 510(k)-cleared devices account for 94% of unplanned postmarket safety studies. More

> Theranos scouts out new lab director amid testing fallout. Article

Biotech News

@FierceBiotech: Gilead wins FDA approval for a new HIV combo pill with rivals at its heels. Report | Follow @FierceBiotech

@JohnCFierce: Andy Futreal at MD Anderson is joining my Big Data:2025 panel at . | Follow @JohnCFierce

> AstraZeneca poaches ZS Pharma for $2.7B, beating Actelion to the punch. Report

> Sanofi bets another $1.7B on diabetes to pad its lagging pipeline. Story

> Under Pfizer's gaze, Allergan's Saunders softens his tone on early-stage R&D. Article

And Finally... Injuries from Mylan's ($MYL) Epipen are rare but have the potential to be serious for children. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.